Inhibikase Therapeutics, Inc. (IKT)
NASDAQ·Healthcare·Biotechnology
$1.88
-0.79%
Mkt Cap $134.20M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 26, 2026 | — | — | — | -$0.12 | -$0.09 | +25.00% | — | — |
| Q4 2025 Nov 14, 2025 | — | — | — | -$0.13 | -$0.13 | +0.00% | — | — |
| Q3 2025 Aug 14, 2025 | — | — | — | -$0.09 | -$0.11 | -22.22% | — | — |
| Q2 2025 May 14, 2025 | — | — | — | -$0.11 | -$0.15 | -36.36% | — | — |
| Q1 2025 Mar 26, 2025 | — | — | — | -$0.10 | -$0.63 | -530.00% | — | — |
| Q4 2024 Nov 14, 2024 | — | — | — | -$0.38 | -$0.65 | -71.05% | — | — |
| Q3 2024 Aug 14, 2024 | — | — | — | -$0.58 | -$0.66 | -13.79% | — | — |
| Q2 2024 May 15, 2024 | — | — | — | -$0.79 | -$0.73 | +7.59% | — | — |
| Q1 2024 Mar 27, 2024 | — | $1 | — | -$0.78 | -$0.63 | +19.23% | — | — |
| Q4 2023 Nov 14, 2023 | — | $79.57K | — | -$1.12 | -$0.86 | +23.21% | — | — |
| Q3 2023 Aug 14, 2023 | — | $116.41K | — | -$0.92 | -$1.11 | -20.65% | — | — |
| Q1 2023 Mar 31, 2023 | — | $64.52K | — | -$0.14 | -$1.02 | -628.57% | — | — |
| Q1 2023 Mar 30, 2023 | — | $123.44K | — | — | -$0.20 | — | — | — |
| Q4 2022 Nov 14, 2022 | $200.00K | $7.29K | -96.35% | -$0.18 | -$1.08 | -500.00% | — | — |
| Q3 2022 Aug 12, 2022 | $300.00K | $6.55K | -97.82% | -$0.19 | -$1.08 | -468.42% | — | — |
| Q2 2022 May 16, 2022 | $300.00K | $46.03K | -84.66% | -$0.17 | -$1.08 | -535.29% | — | — |
| Q1 2022 Mar 31, 2022 | $300.00K | $1.94K | -99.35% | -$0.17 | -$1.20 | -605.88% | — | — |
| Q4 2021 Nov 15, 2021 | $300.00K | $328.46K | +9.49% | -$0.14 | -$1.08 | -671.43% | — | — |
| Q3 2021 Aug 16, 2021 | $300.00K | $1.36M | +354.35% | -$0.38 | -$1.32 | -247.37% | — | — |
| Q2 2021 May 17, 2021 | — | $1.41M | — | — | -$1.56 | — | — | — |